British pharma industry responds to new Brexit guidance from MHRA
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
List view / Grid view
News
EMA safety committee recommends withdrawal of ulipristal acetate marketing authorisation
The EMA's PRAC has recommended the revocation of the marketing authorisation for ulipristal acetate, after a review confirmed liver injury caused by the medicine.
Russia’s Sputnik V COVID-19 vaccine safely elicits an antibody response, reports paper
Preliminary data from Phase I/II trails evaluating the vaccine reveal 100 percent of participants had a humoral and cellular response, with no serious adverse events reported.
Sanofi and GSK initiate Phase I/II trial of COVID-19 vaccine candidate
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.
UK to invest £500 million in next generation COVID-19 testing
Matt Hancock has announced that the £500 million investment will go towards new COVID-19 testing technologies and increased testing capacity.
MHRA issues positive opinion to avelumab for Early Access to Medicines Scheme
The UK MHRA has given a positive scientific opinion for Merck and Pfizer's avelumab on the Early Access to Medicines Scheme (EAMS).
WHO says 172 economies in talks for access to COVID-19 vaccines programme
The WHO has announced that many economies worldwide may participate in COVAX, an initiative aimed at providing countries with equitable access to COVID-19 vaccines.
Hydrocortisone steroid improves COVID-19 patient chance of recovery, study shows
A trial has shown that COVID-19 patients treated with the steroid hydrocortisone had a 93 percent chance of a better outcome from the coronavirus.
Global sterility indicator market to be worth over $1 billion by 2026
According to new research, the global sterility indicator market is set to grow at a CAGR of 10.8 percent over the forecast period.
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
FSD Pharma applies to FDA for trial testing FSD201 in COVID-19 patients
The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients.
Further clinical trials testing Kevzara as COVID-19 therapy to be halted
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
IL-6 signalling blockade alleviates severe COVID-19 symptoms
Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
Phase III testing of AstraZeneca’s AZD1222 vaccine has begun in the US
The clinical study will evaluate the efficacy of AZD1222, a COVID-19 vaccine candidate, in preventing symptomatic COVID-19 at 80 sites across the US.
